BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15153938)

  • 1. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
    Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
    Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
    Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
    Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J
    Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
    Buller RE; Shahin MS; Horowitz JA; Runnebaum IB; Mahavni V; Petrauskas S; Kreienberg R; Karlan B; Slamon D; Pegram M
    Cancer Gene Ther; 2002 Jul; 9(7):567-72. PubMed ID: 12082456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
    Wolf JK; Mills GB; Bazzet L; Bast RC; Roth JA; Gershenson DM
    Gynecol Oncol; 1999 Nov; 75(2):261-6. PubMed ID: 10525383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
    Parker LP; Wolf JK; Price JE
    Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment.
    Atencio IA; Avanzini JB; Johnson D; Neuteboom S; Vaillancourt MT; Nielsen LL; Hajian G; Sutjipto S; Sugarman BJ; Philopena J; McAllister DL; Beltran JC; Nodelman M; Ramachandra M; Wills KN
    Mol Ther; 2001 Jul; 4(1):5-12. PubMed ID: 11472100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
    Song K; Cowan KH; Sinha BK
    Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer.
    Xiang J; Gómez-Navarro J; Arafat W; Liu B; Barker SD; Alvarez RD; Siegal GP; Curiel DT
    J Gene Med; 2000; 2(2):97-106. PubMed ID: 10809143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
    Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
    Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 gene status and chemosensitivity in ovarian cancer.
    Kigawa J; Sato S; Shimada M; Takahashi M; Itamochi H; Kanamori Y; Terakawa N
    Hum Cell; 2001 Sep; 14(3):165-71. PubMed ID: 11774736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
    Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
    You L; Yang CT; Jablons DM
    Cancer Res; 2000 Feb; 60(4):1009-13. PubMed ID: 10706117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
    Mujoo K; Maneval DC; Anderson SC; Gutterman JU
    Oncogene; 1996 Apr; 12(8):1617-23. PubMed ID: 8622881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
    Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK
    Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity.
    Gallardo D; Drazan KE; McBride WH
    Cancer Res; 1996 Nov; 56(21):4891-3. PubMed ID: 8895740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.